

Streamline
Health®

Third Quarter 2021 Earnings Presentation

Nasdaq: STRM



Disclosure Statement

SAFE HARBOR STATEMENT: FORWARD-LOOKING DISCLOSURE

This presentation contains “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, based on current management expectations. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and that can cause Streamline Health’s actual results to differ. We caution you therefore to not place undue reliance on such statements.


Actual results might differ materially from these statements due to a number of risks and uncertainties. Risks that may contribute to the uncertain nature of these statements are described in Streamline Health’s periodic filings made with Securities and Exchange Commission. Special attention is directed to the portions of those documents entitled “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations.” Streamline Health undertakes no obligation to update any forward-looking statements or relevant risks, except as may be required by law.

TRADEMARKS

Product or company names referenced herein may be trademarks or registered trademarks of their respective owners

Third Quarter 2021 & Recent Highlights

SaaS Revenue



214% Growth of SaaS revenue in 3Q21 vs 3Q20. Driven by the acquisition of Avelead



Successful acquisition of Avelead expands revenue and product portfolio

\$6.3M

YTD New Bookings as of October 31, 2021

Sales Update

- Completed the transformation of eValuator salesforce with a team of proven, consultative sales professionals covering the Eastern Seaboard, Great Lakes, Central and Western regions
- Sustained pipeline growth: **23** new prospects added to eValuator pipeline in 3Q
- Maintaining **\$2-\$3M quarterly bookings goal**

Financial Results

Income Statement

	Three Months Ended October 31, 2021	Three Months Ended October 31, 2020	Nine Months Ended October 31, 2021	Nine Months Ended October 31, 2020
Revenue	\$5.5M	\$2.6	\$11.3M	\$8.4M
Operating Expenses	\$9.3M	\$4.5M	\$20.0M	\$13.0M
Loss From Continuing Operations	(\$4.4M)	(\$1.1M)	(\$6.9M)	(\$3.2M)
Net Income/(Loss)	(\$4.3M)	(\$1.1M)	(\$6.5M)	\$1.5M
Adj. EBITDA*	(\$0.3M)	(\$0.7M)	(\$1.7M)	(\$1.7M)




*Streamline Health defines “adjusted EBITDA” as net earnings (loss) plus interest expense, tax expense, depreciation and amortization expense of tangible and intangible assets, stock-based compensation expense, significant non-recurring operating expenses, and transactional related expenses including: gains and losses on debt and equity conversions, associate severances and related restructuring expenses, associate inducements, and professional and advisory fees. Please see our press release for a reconciliation of non-GAAP Adjusted EBITDA to GAAP Net Income.


Financial Results

Balance Sheet

	As of October 31, 2021	As of January 31, 2021
Cash & Cash Equivalents	\$10.4M	\$2.4M
Total Current Assets	\$15.2M	\$7.3M
Total Current Liabilities	\$7.4M	\$7.4M
Total Bank Debt Outstanding	\$10.0M	\$0.0M

Looking Forward

-  Project continued growth of recurring SaaS revenue as a percentage of total revenue
-  Project expansion of SaaS gross margin
-  Anticipate reaching cash generation during 2Q or 3Q 2023



Streamline
Health®

Third Quarter 2021 Earnings Presentation

Nasdaq: STRM

